FDA Chemical Analysis Draft Guidance: What 510(k) Teams Should Recheck

What FDA Published—and What Its Status Means

FDA issued the chemical analysis draft guidance on September 20, 2024. FDA says it is intended to improve the consistency and reliability of analytical chemistry studies submitted to demonstrate medical-device biocompatibility. The draft concentrates on extractables studies: information gathering, test-article extraction, analytical method suitability, compound identification and quantification, the analytical evaluation threshold (AET), and reporting.

The status distinction matters. FDA's page states that the document is a draft, not for implementation. It should therefore be treated as a detailed statement of proposed recommendations—not as a final rule or a universal checklist. The applicable foundation remains FDA's final September 2023 guidance on use of ISO 10993-1, together with current FDA-recognized standards, device-specific guidance and the facts of the particular device.

Which Submission Types May Be Affected?

The draft refers broadly to analytical chemistry studies used in premarket submissions. FDA's final biocompatibility guidance explicitly covers Premarket Notifications (510(k)s), De Novo requests, Premarket Approval applications (PMAs), Investigational Device Exemption applications (IDEs), and Humanitarian Device Exemptions (HDEs) for devices with direct or indirect human-body contact. A chemistry recheck is especially relevant when one of those files:

• uses extractables data and TRA to address systemic toxicity, genotoxicity, carcinogenicity, or reproductive/developmental toxicity;
• uses chemical equivalence to support a material, supplier, manufacturing, sterilization, or configuration change;
• relies on chemistry to justify why additional biological testing is unnecessary; or
• contains coatings, adhesives, colorants, processing aids, degradation products, or sterilization residuals that could affect patient exposure.

Not every device should use the same method. The draft itself points to different or additional approaches for some ophthalmic, respiratory, hemodialyzer and dental devices. It also flags degradable devices, combination products, animal-derived materials, and devices that change physical state during use as cases that may need adaptation and early FDA discussion.

What the Draft Would Change in Practice

• Test-article relevance becomes explicit: describe the final finished device, sterilization, lot, age, packaging or delivery-system contact, and every difference between the tested article and the marketed configuration.
• Clinical preparation should be represented: rinsing or other preparation should follow the instructions for use unless a deviation is scientifically justified. Unrelated pre-rinsing or heating can remove chemicals and undermine relevance.
• Extraction design needs a documented rationale: explain solvent polarity, time, temperature, surface-area-to-volume ratio, agitation, headspace, pooling and any processing of the extract. The draft proposes separate triplicate extractions per solvent unless an alternative is justified.
• Analytical coverage must be demonstrated: show that GC-, LC- and elemental-analysis methods are suitable for the expected analyte range, adequately sensitive to the reporting threshold, and supported by calibration and recovery information.
• Identification confidence must be transparent: distinguish tentative, confident and confirmed identities. An unknown above the AET cannot be made harmless merely by assigning it a retention time and estimated amount.
• TRA inputs must be traceable: connect the highest relevant measured amount, clinical exposure assumptions, identification uncertainty and toxicological evidence to the endpoint conclusion.

Before-and-After Documentation Checklist

• Before: “production-equivalent samples were tested.” Submit instead: exact part numbers, configurations, lots, manufacturing stage, sterilization status, shelf age and a justified comparison with the final finished device.
• Before: extraction parameters appear only in the laboratory appendix. Submit instead: a short strategy explaining why each solvent and condition represents exhaustive or clinically relevant chemical challenge for this device.
• Before: one spreadsheet reports average compound amounts. Submit instead: replicate-level results, blanks, controls, variability, pooling rationale, and the exposure value carried into the TRA.
• Before: the report states that everything above the AET was assessed. Submit instead: the AET equation, every input and unit, the dose-based threshold, clinical-use assumptions, uncertainty factor, and dilution or concentration correction.
• Before: “no toxicological concern” is repeated for each detected chemical. Submit instead: source-specific hazard data, exposure calculations, uncertainty treatment, route/duration relevance and a conclusion mapped to each applicable endpoint.
• Before: the BER summarizes chemistry in a standalone paragraph. Submit instead: an evidence map showing which chemistry and TRA findings support each endpoint decision, residual risk conclusion and proposed test waiver.

Common Failure Modes

• Testing raw materials, an unsterilized build, or a convenient subassembly without bridging it to the finished contacting device.
• Using one solvent, non-clinical pre-rinsing, unreported extract processing, or inappropriate pooling without a device-specific rationale.
• Calculating an AET from an incorrect daily-use assumption or failing to account for repeated devices, dilution, concentration, or analytical uncertainty.
• Reporting unknowns above the AET without further identification work, a conservative toxicological approach, or an explained alternative.
• Using mean replicate results where the selected exposure estimate should capture relevant worst-case variability.
• Treating a chemical profile as an automatic replacement for biological testing rather than one line of evidence in a risk-based evaluation.

Within that stated scope, chemical characterization and TRA may help assess acute, subacute, subchronic and chronic systemic toxicity, genotoxicity, carcinogenicity, and reproductive or developmental toxicity. The draft does not provide a chemistry-only method for local endpoints such as cytotoxicity, sensitization or irritation. Whether any biological test can be omitted therefore depends on the complete risk assessment, available evidence, device contact and FDA's final guidance—not on the existence of an extractables report by itself.

Practical Implications and Next Step

For an existing study, begin with a traceability review before ordering new testing: final device and clinical use → extraction design → analytical coverage → compounds above the reporting threshold → TRA exposure and hazard assumptions → endpoint conclusions. This usually reveals whether the weakness is missing documentation, an analytical limitation, an unresolved toxicological question, or a genuinely unsuitable study design.

Professionals who need a deeper, end-to-end review method can explore the available medical-device chemistry-to-TRA handbook. It connects report fitness, analytical thresholds, exposure assumptions, toxicological reasoning and biological-evaluation integration; its first edition is available by written offer after you inspect the real preview.

For a novel material, unusual device or study that departs materially from the draft, consider seeking FDA feedback before execution through the Q-Submission Program. A Pre-Submission does not guarantee agreement or clearance, but it can surface study-design concerns before time and samples are committed. Any final strategy should also check the current FDA Recognized Consensus Standards database rather than assuming that a previously used edition or recognition decision is still current.